Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;22(1):32-43.
doi: 10.5114/kitp.2025.148514. Epub 2025 Mar 14.

Inflammatory myofibroblastic tumor of the lung: a comprehensive narrative review of clinical and therapeutic insights

Vasileios Leivaditis  1 , Marianthi Baltagianni  2 , Elias Liolis  3 , Nikolaos Baltayiannis  4 , Gabriela Stanc  5 , Efthymia Souka  5 , Pella Batika  1 , Konstantinos Grapatsas  6 , Levan Tchabashvili  7 , Konstantinos Tasios  7 , Andreas Antzoulas  7 , Dimitrios Litsas  8 , Eleftherios Beltsios  9 , Manfred Dahm  1 , Athanasios Papatriantafyllou  1 , Efstratios Koletsis  10 , Francesk Mulita  7
Affiliations
Review

Inflammatory myofibroblastic tumor of the lung: a comprehensive narrative review of clinical and therapeutic insights

Vasileios Leivaditis et al. Kardiochir Torakochirurgia Pol. 2025 Mar.

Abstract

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm classified by the World Health Organization as an intermediate malignancy with less than a 5% chance of metastasis. IMTs consist of myofibroblastic and spindle fibroblastic cells accompanied by inflammatory infiltration, primarily affecting patients under 16 years old, though they can also occur in adults. The etiology and pathogenesis of IMTs remain unclear, with possible contributing factors including inflammation, trauma, autoimmune diseases, prior surgery, viral infections, and uncontrolled myofibroblast proliferation. The primary treatment is complete surgical resection, which is associated with long-term survival and a significantly reduced recurrence rate of 2%, compared to 60% for incomplete resections. Chemotherapy is generally not recommended but may be necessary for unresectable tumors. Advances in histopathological diagnosis provide deeper insights into IMT biology, aiding in the selection of appropriate treatments. This paper presents a comprehensive review of the literature on this rare clinical entity.

Keywords: inflammatory myofibroblastic tumor; mesenchymal tumor; myofibroblastic proliferation; pulmonary inflammatory myofibroblastic tumor; rare lung tumor.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram of the study selection process
Figure 2
Figure 2
A – Computed tomography (CT) scan of the chest reveals a neoplastic mass in the right lower lobe of the lung. B – Positron emission tomography/computed tomography (PET/CT) scan of the lung neoplasm showing a maximum standardized uptake value (SUVmax) of 8.2, indicative of high metabolic activity
Figure 3
Figure 3
Immunohistochemical analysis. A – Vimentin positive staining at 100× magnification. B – Calponin positive staining at 400× magnification. C – Smooth muscle actin (SMA) positive staining at 400× magnification. D – Ki-67 staining at 400× magnification, demonstrating a proliferation index of 1–5% in neoplastic cells
See this image and copyright information in PMC

References

    1. Gleason JE. Idiopathic Myositis involving the extraocular muscles. Opthalmol Rec 1903; 12: 471-478.
    1. Eshraghi B, Sonbolestan SA, Abtahi MA, Mirmohammadsadeghi A. Clinical characteristics, histopathology, and treatment outcomes in adult and pediatric patients with nonspecific orbital inflammation. J Curr Ophthalmol 2019; 31: 327-334. - PMC - PubMed
    1. Pettinato G, Manivel JC, De Rosa N, Dehner LP. Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol 1990; 94: 538-546. - PubMed
    1. Nishadham V, Rao S, Saravanan A, Kulanthaivelu K, Vengalil S, Venkatap- pa HA, Valasani RK, Bardhan M, Pruti N, Nalini A, Mahadevan A. Inflammatory myofibroblastic tumors: a short series with an emphasis on the diagnostic and therapeutic challenges. Clin Neuropathol 2023; 42: 100-111. - PubMed
    1. Coffin CM, Watterson J, Priest JR, Dehner LP. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995; 19: 859-872. - PubMed

LinkOut - more resources